Pharma Pulse 2/10/25: AI Drug Discovery Impact on the Pharma Value Chain, Dementia Is Common and Somewhat Treatable & more

AI Drug Discovery Impact on Pharmaceutical Value Chain

In this interview, Edoardo Madussi, Head of Business Development, Intelligencia AI discusses the potential impact of AI-driven drug discovery platforms like DeepSeek and Qwen, highlighting their democratizing potential while also acknowledging challenges related to data quality and validation. The conversation explores the potential disruptions to current R&D practices, including the acceleration of drug discovery and the optimization of manufacturing and supply chains.

The discussion also addresses the potential risks associated with relying heavily on open-access AI models, including data security, intellectual property concerns, and the potential for biases in underlying datasets. Finally, the interview touches upon the environmental impact of AI, emphasizing the energy consumption of large language models while acknowledging the potential for AI to improve efficiency and reduce the environmental footprint of drug development.

Dementia Is Common and Somewhat Treatable

Many treatments are off-label, so pharmacists can educate clinicians and help patients with access.

Corporate Leaders Are Leaning on AI At Work. How Is It Impacting You?

Companies are investing heavily in AI without seeing real productivity gains. What are workers doing with time saved using new AI tools?

Cencora Reinforces Efforts to Strengthen Pharmaceutical Supply Chain with Expansion of Drug Shortages Mitigation Program

Cencora has expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with reliable access to critical medications, including those at risk of going on shortage. Nearly 200 medications — including several oncology treatments — are now available through the program, which represents an increase of more than 350% since the program launched in 2021.

Rob Beese on LinkedIn

Wholesalers and pharmaceutical manufacturers do not have the same opinions on Fair Market Value (FMV) assessments during negotiations despite their importance to pharma. My article in Pharmaceutical Commerce Magazine looks at re-purposing Current Market Leverage (CML) to describe additional considerations that may help align internal financial and operational expectations for #pharma.
Archbow Consulting

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs